HCV / Hepatitis

The FDA's accelerated approval of bulvirtide for chronic hepatitis D headlined May's news. Learn more about the treatment's phase 3 clinical trial including its efficacy, safety profile, and clinician insights. May also included Viral Hepatitis Awareness Month and National Hepatitis Testing Day. Listen to a clinician talk about the significance of these awareness events.

Modeling of the ACIP recommendation to replace universal birth-dose HepB vaccination with vaccination based on "shared decision" and maternal status shows substantially more maternal screening or vaccinating infants of unscreened mothers will be necessary to mitigate increase in infections.

The FDA has approved bulevirtide-gmod (Hepcludex), the first approved US therapy for HDV with no prior treatment options.

Universal childhood immunizations should continue to include hepatitis A to avoid reversing 3 decades of progress toward eliminating the infection, say contributors to the previous, long-standing CDC guidance.

This week, read about shorter treatment duration for community-acquired pneumonia, how integrating hepatitis C EMR prompts and innovative community outreach are increasing patients getting tested and treated, and how professional medical organizations are leading the fight for vaccines.

This week, read a clinician's insights on a new FDA-approved HIV therapy, the CDC cancels publication of a COVID-19 vaccine study, moving up hepatitis C cure timelines, and more.

Emerging evidence suggests that confirming hepatitis C cure at 4 weeks post-treatment could improve patient engagement and reduce barriers to care without compromising accuracy. Meghan D. Morris, PhD, MPH, offers insights around her study on this subject.

This week, read about AI and antibiotic development, an innovative hepatitis C program to get postpartum mothers tested and treated sooner, on World Liver Day a nurse talks about her personal story and how she advocate for better education around this vital organ, and more.

In honor of World Liver Day 2026, a nurse shares the heartbreaking story of her son’s fatal liver disease and her lifelong mission to educate the public about the often overlooked role of the liver.

A nurse’s decades-long advocacy highlights how personal loss and gaps in public education have shaped ongoing challenges in hepatitis B vaccination and liver disease awareness.

New research from UC San Francisco (UCSF) suggests hepatitis C cure may be reliably confirmed as early as four weeks after treatment, potentially improving care access for underserved populations.

The rate of HBV vaccination of newborns in the US has declined by over 10% in the past 2 years, reversing decades of increasing coverage.

New in vitro data presented at CROI show that Atea Pharmaceuticals’ oral nucleotide analogue AT-587 demonstrates markedly superior potency against hepatitis E virus compared with existing off-label options, supporting plans to advance the candidate into phase 1 clinical development in 2026.

Here are some therapeutics and a vaccine that will be reporting data, starting a trial, or filing their data to regulatory agencies in order to seek approval this year.

The recent CDC ACIP meetings and subsequent actions show a path for which the current Health and Human Services department wants to roll back access to vaccines for this virus and other vaccines.

Agreement supports commercialization and reimbursement efforts for tobevibart plus elebsiran as the ECLIPSE clinical program advances, including completion of enrollment for the ECLIPSE 3 trial.

The single-source award will fund a large randomized trial evaluating mortality, morbidity, and developmental outcomes following the hepatitis B birth dose, amid ongoing debate over non-specific vaccine effects.

This new recommendation relates to infants born to women who test negative for hepatitis B. This is a departure from the federal agency’s previous recommendation and comes on the heels of the ACIP’s recent meeting.

This week, read our coverage on the CDC ACIP meetings on the hepatitis B virus (HBV) vaccine, modeling data on the potential consequences of HBV infections, liver cancer, and mortality when delaying the birth dose to 2 months, our latest podcast, and more.

Lacking any safety data showing potential serious adverse effects, the committee decided to move forward with the recommendation “that the initial dose is administered no earlier than 2 months of age.”

Due to repetitive and confusing language, the committee decided to amend the votes for clarity and will vote on 3 new recommendations on Friday.

A new analysis shows thousands of children could contract hepatitis B, leading to further complications and deaths, if the vaccine schedule recommendations are changed to later in a child's life.

New modeling and clinical data presented by Atea Pharmaceuticals suggest that its fixed-dose combination of bemnifosbuvir and ruzasvir could offer a potent, short-duration, best-in-class treatment option for hepatitis.

A mother recounts her newborn son's fatal battle with cirrhosis reminding people of the importance of health and education about this vital organ.

Primary completion is expected in Q4 2026 with topline results in Q1 2027, while ECLIPSE 2 and 3 continue enrolling to support potential US and EU submissions.